Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Multiple Sclerosis Clinical Trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (565) clinical trials

6.1 PRIMARY The primary objective of the study is to evaluate treatment satisfaction as the primary Patient- Reported Outcome (PRO) in patients with relapsing forms of MS (RMS) treated with LEMTRADA in a real life setting using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. 6.2 SECONDARY The secondary ...

Phase N/A

Multiple sclerosis (MS) is a chronic and often disabling disorder of the central nervous system involving damage to the brain, optic nerves and spinal cord. Most patients initially present with relapsing remitting MS, experiencing unpredictable episodes of transient neurological deterioration (relapse) followed by a variable period of recovery (remission) during ...

Phase N/A

The purpose of this prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further monitor the overall safety profile of fingolimod under conditions of routine medical practice and to explore the incidence of selected safety related outcomes. ...

Phase

To assess early phase safety and tolerability of converting patients from approved oral and injectable RMS DMTs to siponimod. The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod and provide clinically relevant data on safety and tolerability for ...

Phase

The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to continued SID treatment. The secondary objectives are to evaluate additional clinical and ...

Phase

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other ...

Phase N/A

The goal of this study is to learn more about Magnetic Resonance Imaging (MRI) and cognitive function over a 12 month period in people who have switched DMTs. In addition to your regular clinical care, you will be asked to answer questions about your health and complete the Single Digit ...

Phase N/A

The primary purpose of this study is to demonstrate pharmacokinetic bioequivalence of ofatumumab injected by Pre-filled Syringe (PFS) versus Auto-Injector (AI) devices and thereby establish a bridge between the ongoing Phase 3 program and the to-be-marketed drug-device combinations.

Phase

The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.

Phase N/A

This study will assess the safety, tolerability, and efficacy of suvorexant in multiple sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment period 1 with either suvorexant or matching placebo (1:1). After treatment period 1, subjects will undergo a washout period of 1 week then 2 weeks ...

Phase